Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Cabaletta Bio, Inc.

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in systemic lupus erythematosus and myositis, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.

5AM Ventures

Baker Brothers Advisors LLC

Boxer Capital

Cormorant Capital

Deerfield Capital Management

Penn Medicine Co-Investment Program

Redmile Group

Adage Capital Management

Cabaletta Bio

Cabaletta Bio recognizes and congratulates Georg Schett, innovator and global leader in the use of CD19-targeting cell therapies for patients with autoimmune diseases, along with his team on their landmark publication in the New England Journal of Medicine. Their academic case series study demonstrated durable clinical responses across 15 patients (8 with lupus, 3 with myositis and 4 with systemic sclerosis) treated with a 4-1BB co-stimulatory domain containing autologous CD19-CAR T construct. We believe these published data represent a pivotal moment in the effort to bring potentially transformative treatment to patients with a broad range of autoimmune diseases. #CART #autoimmunity #lupus #myositis #scleroderma https://lnkd.in/eU_KVCwH

Cabaletta Bio is excited to announce that the FDA has granted orphan drug designation to CABA-201 for the treatment of myositis. This designation is an important recognition for investigational therapies in rare diseases as we seek to deliver the first targeted, potentially curative, cell therapy for patients with autoimmune disease. Cabaletta's RESET-Myositis and RESET-SLE trials are currently enrolling patients [https://lnkd.in/eXEnYuh2, https://lnkd.in/eXHmWhbG] #CART #autoimmune #myositis. https://lnkd.in/exzwpp_n


Dr. Gwendolyn Binder PhD, President of Science and Technology at Cabaletta Bio, will be delivering the opening keynote presentation at the 7th annual Cell & Gene Therapy Innovation Summit where she will review the history and current state of art for engineered T cell therapy for patients with autoimmune diseases. Join us in Barcelona on Wednesday, February 7, 2024 in Barcelona for the presentation!

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	189K -	603K 219.05%	920K 52.57%	1.24M 35.11%	2.33M 87.69%	2.46M 5.57%	4.55M 84.61%
accumulated other comprehensive income loss				6K -		-47K -	39K 182.98%
cash and cash equivalents	1K -	33.02M 3,301,600%	136.20M 312.53%	101.43M 25.53%	122.22M 20.50%	81.61M 33.23%	193.24M 136.79%
cash and short term investments	1K -	33.02M 3,301,600%	136.20M 312.53%	108.66M 20.22%	122.22M 12.48%	106.55M 12.83%	241.25M 126.42%
common stock
deferred revenue
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt						2.96M -	1.46M 50.73%
long term investments
net debt	-1K -	-33.02M 3,301,600%	-136.20M 312.53%	-101.43M 25.53%	-122.22M 20.50%	-76.47M 37.43%	-188.22M 146.14%
net receivables
other assets							1 -
other current assets		977K -	4.35M 345.04%	4.87M 12.07%	2.32M 52.41%	2.29M 1.38%	3.24M 41.71%
other current liabilities	61K -	340K 457.38%	2.23M 555%	3.94M 76.78%	6.05M 53.59%	4.85M 19.84%	7.89M 62.72%
other liabilities	-189K -
other non current assets		180K -	101K 43.89%	299K 196.04%	357K 19.40%	565K 58.26%	1.71M 202.48%
other non current liabilities		43.92M -
othertotal stockholders equity	1K -	1.76M 176,100%	29.81M 1,591.94%	175.84M 489.82%	230.54M 31.11%	270.13M 17.17%	469.40M 73.77%
preferred stock			141.47M -
property plant equipment net			815K -	890K 9.20%	1.44M 61.57%	7.57M 426.36%	7.45M 1.56%
retained earnings	-250K -	-12.45M 4,880.80%	-32.96M 164.69%	-66.30M 101.15%	-112.59M 69.82%	-165.56M 47.05%	-233.24M 40.88%
short term debt						2.18M -	3.56M 63.38%
short term investments				7.23M -		24.94M -	48.01M 92.51%
tax assets
tax payables
total assets	1K -	34.17M 3,417,300%	141.47M 313.96%	114.72M 18.90%	126.34M 10.12%	116.97M 7.42%	253.65M 116.85%
total current assets	1K -	33.99M 3,399,300%	140.55M 313.46%	113.53M 19.22%	124.54M 9.69%	108.83M 12.61%	244.49M 124.64%
total current liabilities	250K -	943K 277.20%	3.15M 233.72%	5.18M 64.60%	8.38M 61.78%	9.49M 13.23%	15.99M 68.55%
total debt						5.14M -	5.02M 2.34%
total investments				7.23M -		24.94M -	48.01M 92.51%
total liabilities	250K -	44.86M 17,845.60%	3.15M 92.99%	5.18M 64.60%	8.38M 61.78%	12.45M 48.54%	17.45M 40.20%
total liabilities and stockholders equity	1K -	34.17M 3,417,300%	141.47M 313.96%	114.72M 18.90%	126.34M 10.12%	116.97M 7.42%	253.65M 116.85%
total non current assets		180K -	916K 408.89%	1.19M 29.80%	1.79M 50.97%	8.13M 353.15%	9.16M 12.61%
total non current liabilities	189K -	43.92M 23,138.62%				2.96M -	1.46M 50.73%
total stockholders equity	-249K -	-10.69M 4,193.17%	138.32M 1,393.93%	109.54M 20.80%	117.96M 7.68%	104.52M 11.39%	236.20M 125.98%

COM:CABALETTABIO

Cabaletta Bio, Inc.

Last Close

5.79

30/08 20:00

Market Cap

380.90M

Beta: -

Volume Today

850.64K

Avg: -

Preview